For Prostate Cancer, The Roswell Park Team Discovers A Tumor Suppressant Protein

Study results support development of LRIG1 as novel anti-cancer therapeutic

  • Study is first to report that LRIG1 suppresses prostate cancer development
  • LRIG1-derived peptide now being developed as anti-cancer therapeutic
  • LRIG1 expression levels in tumors could become prognostic biomarker

A research team led by a scientist at Roswell Park Comprehensive Cancer Center has identified the molecule LRIG1 as an important endogenous tumor suppressor in prostate cancer. Writing in the journal Nature Communications, the team documents their findings from preclinical studies showing that overexpression of the LRIG1 protein inhibits prostate cancer development, while reducing naturally occurring LRIG1 promotes prostate tumor development.

dean-tang-enviromental.jpg
Roswell Park's Dean Tang, PhD, led a team that has identified a new prostate cancer suppressor protein.

Dean Tang, PhD, Professor and Chair of Pharmacology and Therapeutics at Roswell Park Comprehensive Cancer Center, is the senior author of the study, whose findings, he says, have compelled researchers to look at how best to incorporate LRIG1, a protein naturally expressed in patient tumor cells, into treatment for prostate cancer patients.

“Interestingly, the LRIG1 gene is induced in developing tumors, presumably representing the patient’s defense mechanism against tumor growth,” Dr. Tang says. “The LRIG1 expression levels in patients’ tumors could potentially be developed into a prognostic biomarker — the higher the expression level, the better prognosis for prostate cancer patients.”

While the protein is not yet available as a therapeutic, Dr. Tang and team are working to develop it into an LRIG1-derived peptide, which, if those efforts are successful, could be used as anti-cancer therapeutic via intravenous injection.

This approach could potentially be an effective strategy for treating patients with inoperable prostate cancer. Prostate cancer is one of the most common and treatable types of cancer in men, with five-year survival rates reaching nearly 100% thanks to advances in detection and treatment.

However, prostate cancer remains the second-leading cause of male cancer deaths, because those with more advanced or aggressive forms of the disease eventually experience progression or recurrence despite treatment. Standard therapy uses drugs that target and block the androgen receptor (AR), a protein that binds to androgens (male hormones) to stop or inhibit prostate cancer cell growth. But the results often don’t last, and many patients develop castration-resistant prostate cancer — an aggressive, treatment-resistant form of the disease — within a year of anti-androgen therapy.

“The good news for prostate cancer patients is that LRIG1 also possesses therapeutic efficacy and is actually up-regulated in tumors, in response to several oncogenic signals,” notes Dr. Tang. “This new research represents a comprehensive exploration of LRIG1 expression, functions and mechanisms in prostate cancer, and advocates a novel conceptual paradigm that LRIG1 represents a pleiotropic-feedback tumor suppressor induced by multiple oncogenic signaling pathways.”

This research was supported by grants from the National Cancer Institute (project nos. R01CA155693, R01CA237027, R01CA240290, R21CA218635 and P30CA016056), U.S. Department of Defense (award nos. W81XWH-14-1-0575, W81XWH-16-1-0575 and W81XWH-15-1-0366), Chinese Ministry of Science and Technology (grant 2016YFA0101201) and the National Natural Science Foundation of China (grant nos. 81602592 and 81802973). 

The study, “LRIG1 is a pleiotropic androgen receptor-regulated feedback tumor suppressor in prostate cancer,” can be read at www.nature.com.

###

For an online version of this release, please visit: https://www.roswellpark.org/newsroom/201912-roswell-park-team-identifies-new-tumor-suppressor-protein-prostate-cancer

Roswell Park Comprehensive Cancer Center is a community united by the drive to eliminate cancer’s grip on humanity by unlocking its secrets through personalized approaches and unleashing the healing power of hope. Founded by Dr. Roswell Park in 1898, it is the only National Cancer Institute-designated comprehensive cancer center in Upstate New York. Learn more at www.roswellpark.org, or contact us at 1-800-ROSWELL (1-800-767-9355) or ASKRoswell@RoswellPark.org

For Prostate Cancer, The Roswell Park Team Discovers A Tumor Suppressant Protein

For Prostate Cancer, The Roswell Park Team Discovers A Tumor Suppressant Protein

Roswell Park

1 week
7 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Up Next Autoplay
Lymphopenia: How This Affects Clinicians and Treatment Today @CleClinicNews
Lymphopenia: How This Affects Clinicians and Treatment Today @CleClinicNews
Category: Non-Hodgkin Lymphoma
3 Views
Cancer-News 19 hours
HORIZON Study #ASH19 @RushMedical
HORIZON Study #ASH19 @RushMedical
Category: Multiple Myeloma
0 Views
ash 20 hours
Immune Status, Inflammation Can Predict Mortality @CleClinicNews @CleClinicMD
Immune Status, Inflammation Can Predict Mortality @CleClinicNews @CleClinicMD
Category: Non-Hodgkin Lymphoma
0 Views
Cancer-News 20 hours
Phase I Study of Duvelisib in CLL/SLL #ASH19 #ASH @DanaFarber
Phase I Study of Duvelisib in CLL/SLL #ASH19 #ASH @DanaFarber
Category: Chronic Lymphocytic Leukemia
11 Views
ash 1 day
MANIFEST, a Phase 2 Study of CPI-0610 @MountSinaiNYC #ASH #ASH19
MANIFEST, a Phase 2 Study of CPI-0610 @MountSinaiNYC #ASH #ASH19
Category: Other
0 Views
ash 1 day
Phase I Study Evaluating NKTR-255 in MM and NHL #ASH #ASH19 @DanaFarber
Phase I Study Evaluating NKTR-255 in MM and NHL #ASH #ASH19 @DanaFarber
Category: Multiple Myeloma
0 Views
ash 1 day
Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of  Hematology (ASH) 2019 Annual Meeting
Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of Hematology (ASH) 2019 Annual Meeting
Category: Immunotherapy
2 Views
cancernewsupdate 2 days
New PreClinical Data for its IL-15 Agonist, NKTR-255 #ASH19 #ASH
New PreClinical Data for its IL-15 Agonist, NKTR-255 #ASH19 #ASH
Category: Immunotherapy
1 Views
ash 2 days
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Category: Breast Cancer
2 Views
cancernewsupdate 2 days
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL: How This Affects Clinicians? #ASH19 #ASH
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL: How This Affects Clinicians? #ASH19 #ASH
Category: Chronic Lymphocytic Leukemia
0 Views
ash 2 days